13th Annual BIO Asia International Conference
Grand Hyatt TokyoTokyo, JAPAN Visit the Venue to read more
The BIO Asia International Conference, co-hosted by the Biotechnology Industry Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market.
Who Should Attend
Drug development and discovery companies
Medical technology companies
Universities and institutes
Intellectual property and legal organizations
Investors and financial services providers
Bio-clusters and incubators
Government and public support agencies
Managing Director, Lazard
Andrew Dickinson joined Lazard's Healthcare Group in 2007 and is a Managing Director based in San Francisco. Mr. Dickinson has advised on transactions including the acquisition of ViroPharma for Shire, the acquisition of Onyx for Amgen, the acquisition of Human Genome Sciences for GSK, the sale of Anadys to Roche, the sale of Abraxis BioScience to Celgene, the sale of Oriel to Novartis/Sandoz, the acquisition of Noven for Hisamitsu, the sale of APP to Fresenius and the sale of Aspreva to Galenica. Prior to joining Lazard, Mr. Dickinson served as a Senior Legal Advisor to Gilead Sciences and as General Counsel and Vice President of Corporate Development at Myogen, Inc. While at Myogen, Mr. Dickinson managed the strategic process that culminated in Gilead's acquisition of Myogen (2006) and led complex licensing and partnership transactions, including a research and development collaboration with Novartis and a commercial development collaboration with GlaxoSmithKline. Prior to joining Myogen, Mr. Dickinson worked at Cooley Godward LLP and Kirkland & Ellis, LLP where he advised on public and private merger and acquisition transactions as well as debt and equity offerings, private equity fund formations and venture capital financings. University of Colorado, B.A. in Molecular, Cellular and Developmental Biology, Loyola University of Chicago, J.D. (cum laude)
Japan/Asia Advisor, Verastem
Steve brings over 20 years of senior executive level operating and transaction experience in the biopharmaceutical industry, with world-class expertise in Japanese/Asian markets. In March 2014, he established his own consultancy, Renegen LLC, and is supporting clients including Verastem, Inc. and Locust Walk Partners, where he leads partnering and transaction initiatives with companies in Japan and Asia.
Prior to joining establishing Renegen LLC, Steve headed the Japanese operations of Shire Pharmaceuticals. In this capacity, he oversaw the integration of the rare disease and specialty pharma business units, and the filing of the first two Japanese NDAs for Shire’s Japan business. Before Shire, Steve served as CEO of Solasia Pharma KK, a cancer-focused development stage company. Raising over $40MM in venture capital, he built a portfolio of novel cancer drugs and established operations in Japan and China. Steve launched his biopharma career at Purdue Pharma in business development, and then held the position of President of Purdue’s Japanese subsidiary for nine years. In this role, he oversaw the development and commercialization of the company’s leading pain management franchise.
Steve, his wife, and two daughters have their primary residence in Tokyo and a second home in Salt Lake City. Steve is fluent in written and spoken Japanese.
Global Head-Emerging Therapies and Market Development, Baxter BioScience
John Glasspool is Head of Market Development and Emerging Therapies in Baxter Bioscience.
Prior to joining Baxter in August 2012, John was Head Region Europe and Novartis Vaccines & Diagnostics (V&D), a member of the V&D Executive Committee.
John served as a board member, Vice President and President of the European Vaccine manufacturers (EVM), from 2010 until December 2012
Previously, John was Head of Global Pricing & Market Access, and Head of Global Commercial Operations in Novartis Pharma, where he led the functions in embedding the needs of customers and consumers for brands at all stages of their lifecycle -- development, launch and in market.
John joined Novartis Head of Marketing for NeuroScience. He was promoted to Global Head CardioVascular & Metabolism Business Franchise in 2006, during which time he grew the franchise sales from $4.9 Bn in 2004 to $6.7 Bn over a three-year period.
Before joining Novartis, John worked for J&J in Pharmaceuticals and Consumer, launching products in the Europe, US, and for J&J Corporate in Global Strategic Marketing. John held a number of positions with J&J during his career there including hospital sales, project and product manager, before becoming the Neurology Business Head responsible for marketing & sales and then Neurology European Business Director. Prior to working at J&J, John worked at a small startup company selling ethical products to GP's and a range of over the counter products to pharmacies.
Before joining the pharmaceutical industry, John owned a restaurant and small hotel.
While always holding commercial roles, John has been granted 2 patents. One is in neuroscience on “statin therapy for enhancing cognitive maintenance” (EP 1 492 539 B1) by European Patent Office on 28 June 2003. This patent relates to a method of treating dementia as a result of Alzheimer’s Disease, or a memory disorder. The other one is in cardiovascular on the “use of iron chelator for the treatment of myocardial infarction” by World Intellectual Property Organization on 20 November 2008.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Grand Hyatt Tokyo
6-10-3 Roppongi, Minato-Ku
Tokyo, Japan 106-0032
Senior Manager, Sales and Sponsorship
Biotechnology Industry Organization (BIO)
1201 Maryland Avenue, SW, Suite 900
Washington, D.C. 20024
Phone: (202) 312-9278
Interested in showcasing both your company and your support for the conference? Custom sponsorship packages are available with benefits including:
Prominent speaking opportunities
Dedicated sponsor suites for private meetings
Priority customer service & partnering meeting scheduling
High-visibility branding opportunities
Corporate recognition on event marketing materials:
Pre-conference marketing collateral
Advertisement in on-site program book
For more information on BIO sponsorships, please visit www.bio.org/sponsor.
BIO Contact Information
1201 Maryland Avenue, SW
Washington, DC 20024